Non-Invasive Measurements of Changes in Pulmonary Artery Pressure in Intensive Care Unit Patients Using Electrical Impedance Tomography - A Feasibility Study
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Aug 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to measure changes in pulmonary artery pressure (PAP) in critically ill patients using a special chest belt called electrical impedance tomography (EIT). This method is non-invasive, meaning it doesn’t require any surgery or insertion of devices into the body, unlike the traditional method which uses a catheter. The goal is to see if the EIT measurements are accurate enough to replace the more invasive technique in monitoring patients in the Intensive Care Unit (ICU) who are experiencing pulmonary artery hypertension.
To participate in this study, patients must be at least 18 years old, be intubated, and have a medical need to monitor their PAP and heart function using a pulmonary artery catheter. However, certain patients are not eligible, such as those with specific electronic devices in their chest, pregnant or nursing women, or those with certain injuries or skin conditions. Participants can expect to wear the EIT chest belt during their treatment, and researchers will compare its readings to the traditional method to evaluate its effectiveness. This study is currently recruiting participants, and it aims to improve how doctors monitor heart and lung health in critically ill patients.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Age ≥ 18-year-old.
- • Intubated patients in the ICU with clinical decision to monitor PAP and cardiac output using a PAC.
- Exclusion criteria:
- • Patients with implanted or external thoracic electronic devices (e.g., pacemaker) or thoracic metal implants.
- • Known pregnancy or lactating patients.
- • Open lung injuries or pneumothorax.
- • Open wounds, drainages, burns or rashes of the upper thorax.
- • Estimated thoracic perimeter smaller than 66 cm or larger than 134 cm.
- • Known allergies to wound dressings or adhesives (e.g., gel electrodes)
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Kaspar F Bachmann, MD
Principal Investigator
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Carmen A Pfortmueller, MD
Study Director
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported